in compliance with GMP, ICH Q1A, and USP standards.

2. Scope

This SOP applies to all compatibility assessments carried out on primary packaging components including vials, stoppers, seals, prefilled syringes, and cartridges intended for use in sterile injectable product development.

3. Responsibilities

• Formulation Development Scientist: Identifies packaging systems and initiates compatibility studies.
• Analytical Development (QC): Performs testing related to extractables/leachables, integrity, and chemical interaction.
• QA: Ensures protocol and final report compliance with regulatory requirements.
• Packaging Development: Supports selection of suitable container closure systems.

4. Accountability

The Head of Formulation Development is accountable for ensuring appropriate execution of container closure compatibility studies and documentation thereof.

5. Procedure

5.1 Selection of Container Closure System

1. Select candidate container systems based on:
   • Material of construction
   • Drug product characteristics (pH, solvent type, reactivity)
   • Intended route of administration
2. Record system specifications (Annexure-1).

5.2 Preparation of Study Protocol

1. Prepare a protocol including:
   • Objective and study design
   • Test parameters (e.g., adsorption, leaching, integrity)
   • Sample size and timepoints
2. QA shall review and approve the protocol before study initiation.

5.3 Sample Preparation and Storage

1. Fill sterile injectable formulation into proposed containers under aseptic conditions.
2. Seal using validated capping or stoppering equipment.
3. Label with identification details including:
   • Study code
   • Storage condition
   • Date of filling

5.4 Testing Parameters

1. Conduct the following tests as applicable:
   • Extractables/Leachables: Use GC-MS, ICP-MS or LC-MS/MS
   • Container Closure Integrity: Perform dye ingress, vacuum decay, or helium leak test
   • Adsorption: Evaluate active loss by assay reduction
   • Chemical Interaction: Check for visible interaction, pH change, and degradation
   • Moisture permeability: Especially for lyophilized products
2. Record data in the Compatibility Testing Log (Annexure-2).

5.5 Evaluation and Interpretation

1. Review test results against acceptance criteria mentioned in the protocol.
2. Investigate any deviations or failure to meet criteria as per SOP.
3. Prepare the final report including:
   • All raw data, observations, and conclusions
   • Packaging component recommendations
4. Submit final report for QA approval (Annexure-3).

6. Abbreviations

• SOP: Standard Operating Procedure
• QA: Quality Assurance
• QC: Quality Control
• GC-MS: Gas Chromatography-Mass Spectrometry
• ICP-MS: Inductively Coupled Plasma Mass Spectrometry
• LC-MS: Liquid Chromatography–Mass Spectrometry

7. Documents

1. Container Closure Specification Record – Annexure-1
2. Compatibility Testing Log – Annexure-2
3. Final Compatibility Study Report – Annexure-3

8. References

• ICH Q1A(R2): Stability Testing of New Drug Substances and Products
• USP <1207>: Package Integrity Evaluation
• FDA Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics

9. SOP Version

Version: 2.0

10. Approval Section

	Prepared By	Checked By	Approved By
Signature
Date
Name
Designation	Formulation Scientist	QA Reviewer	QA Head
Department	R&D	Quality Assurance	Quality Assurance

11. Annexures

Annexure-1: Container Closure Specification Record

Container Type	Material	Manufacturer	Specification No.
10 mL Vial	Type I Glass	Borosil Pharma	VIAL-GL-001
Stopper	Bromobutyl Rubber	West Pharma	STOP-RB-009

Annexure-2: Compatibility Testing Log

Date	Test Performed	Result	Remarks	Tested By
12/06/2025	Extractables	Complies	No organic leachables	Sunita Reddy
15/06/2025	CCIT (Vacuum Decay)	Pass	Integrity maintained	Rajesh Kumar

Annexure-3: Final Compatibility Study Report

Study Title	Compatibility Study for Product A with Vial-Stopper-Flip Off Seal System
Duration	3 Months Accelerated & Long-Term
Outcome	Container closure system found compatible
Prepared By	Arvind Joshi
Approved By	QA Head

Revision History

Revision Date	Revision No.	Details	Reason	Approved By
12/01/2022	1.0	Initial Release	New SOP	QA Manager
18/06/2025	2.0	Aligned with USP <1207> and ICH Q1A updates	Annual Review	QA Manager